BackSigilon Therapeutics Overview

Sigilon Therapeutics Receivables

Sigilon Therapeutics's receivables is $6.9M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$6.86M
29717.39% YoYΔ $6.83M vs prior year quarter

Peer trimmed avg / median

Loading

Sigilon Therapeutics Receivables History

Loading

Sigilon Therapeutics vs. peers: Receivables Comparison

Loading

Sigilon Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sigilon Therapeutics (SGTX) FAQ

As of the most recent data (June 2023), SGTX shows a receivables of $6.9M. That compares with $23K in the prior-year period — up 29717.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SGTX's receivables is now $6.9M (was $23K) — a 29717.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sigilon Therapeutics is outperforming or lagging.

Tracking SGTX's receivables over time shows whether Sigilon Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $6.9M That compares with $23K in the prior-year period — up 29717.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Sigilon Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $6.9M) with ownership activity and broader fundamentals.

Sigilon Therapeutics's receivables is $6.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.